Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class